He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.
View all episodes
By BiotechTV
5
44 ratings
He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.
30,626 Listeners
1,863 Listeners
1,085 Listeners
325 Listeners
6,059 Listeners
60 Listeners
9,840 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
497 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners